NASDAQ: PMNPromis Neurosciences Inc Stock
$2.05-0.01 (-0.49%)
Updated Apr 23, 2024
PMN Price
$2.05
Fair Value Price
$0.75
Market Cap
$38.87M
52 Week Low
$0.95
52 Week High
$8.95
P/E
-1.92x
P/B
10.36x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$13.21M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
2.63
Operating Cash Flow
-$11M
Beta
0.49
Next Earnings
May 13, 2024
Ex-Dividend
N/A
Next Dividend
N/A
PMN Overview
ProMIS Neurosciences, Inc. discovers and develops precision medicine solutions for the treatment of neurodegenerative diseases, primarily Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA) in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a superoxide dismustase 1 and TAR-DNA binding protein 43 in ALS, as well as alpha synuclein in Parkinson's disease and Lewy body dementia; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils in MSA. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how PMN scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
PMN ($2.05) is overvalued by 173.33% relative to our estimate of its Fair Value price of $0.75 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
PMN ($2.05) is not significantly undervalued (173.33%) relative to our estimate of its Fair Value price of $0.75 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
PMN is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more PMN due diligence checks available for Premium users.
Be the first to know about important PMN news, forecast changes, insider trades & much more!
PMN News
Valuation
PMN fair value
Fair Value of PMN stock based on Discounted Cash Flow (DCF)
Price
$2.05
Fair Value
$0.75
Overvalued by
173.33%
PMN ($2.05) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
PMN ($2.05) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
PMN is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
PMN price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.92x
Industry
16.46x
Market
41.92x
PMN price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
10.36x
Industry
5.93x
PMN is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
PMN's financial health
Profit margin
Revenue
$0.0
Net Income
-$3.6M
Profit Margin
0%
PMN's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$13.6M
Liabilities
$9.9M
Debt to equity
2.63
PMN's short-term assets ($13.62M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
PMN's short-term assets ($13.62M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
PMN's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$3.8M
Investing
-$1.3k
Financing
-$510.6k
PMN's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
PMN vs Biotech Stocks
Promis Neurosciences Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.